Alexion Pharmaceuticals Inc. (ALXN)

133.51
2.58 1.90
NASDAQ : Health Technology
Prev Close 136.09
Open 136.04
Day Low/High 132.86 / 136.39
52 Wk Low/High 92.56 / 140.77
Volume 1.66M
Avg Volume 1.76M
Exchange NASDAQ
Shares Outstanding 223.47M
Market Cap 30.33B
EPS 0.30
P/E Ratio 385.37
Div & Yield N.A. (N.A)
Alexion Pharmaceuticals, Incyte, Walt Disney: 'Mad Money' Lightning Round

Alexion Pharmaceuticals, Incyte, Walt Disney: 'Mad Money' Lightning Round

Jim Cramer's bullish on Alexion Pharmaceuticals and Incyte. But, he says, Disney's good for the long term.

Alexion To Report Second Quarter 2017 Results And Strategic Update On Thursday, July 27, 2017

Alexion To Report Second Quarter 2017 Results And Strategic Update On Thursday, July 27, 2017

Alexion Pharmaceuticals, Inc. (Nasdaq: ALXN) today announced that the Company will report its financial results for the second quarter 2017 on Thursday, July 27, 2017 before the US financial markets open.

Alexion Investigation Believed to Have 'Minimal Impact'

Alexion Investigation Believed to Have 'Minimal Impact'

Investors shouldn't ruffle their feathers. At least, not yet.

Biotech Movers: Alexion, Arena, Novavax

Biotech Movers: Alexion, Arena, Novavax

Alexion, Arena and Novavax were among the biotech stock movers ahead of the market open on Friday, July 7.

Alexion Reaches Funding Agreement With NICE And NHS England For Strensiq® (asfotase Alfa) For Patients With Pediatric-onset Hypophosphatasia (HPP)

Alexion Reaches Funding Agreement With NICE And NHS England For Strensiq® (asfotase Alfa) For Patients With Pediatric-onset Hypophosphatasia (HPP)

Alexion Pharmaceuticals, Inc. (NASDAQ: ALXN) today announced that it has reached a national funding agreement with the National Institute for Health and Care Excellence (NICE) and the National Health Service (NHS) England...

Who's Afraid of the Amazon Empire?: Cramer's 'Mad Money' Recap (Thursday 6/22/17)

Who's Afraid of the Amazon Empire?: Cramer's 'Mad Money' Recap (Thursday 6/22/17)

Jim Cramer doesn't buy the backlash against Amazon. He says Prime is a very powerful tool and an irresistible bargain.

Alexion Receives Positive CHMP Opinion For Soliris® (Eculizumab) For The Treatment Of Patients With Refractory Generalized Myasthenia Gravis (gMG) In The European Union

Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) announced today that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion to extend the current...

Citigroup, Zoetis, AbbVie, Mattel, Valeant Pharmaceuticals 'Mad Money' Lightning Round

Citigroup, Zoetis, AbbVie, Mattel, Valeant Pharmaceuticals 'Mad Money' Lightning Round

Jim Cramer is bullish on Citigroup, Zoetis, Idexx Labs, AbbVie, Nucor, and Alexion.

Dow and S&P 500 Dive Further From Records as Oil Price Rout Rages On

Dow and S&P 500 Dive Further From Records as Oil Price Rout Rages On

The S&P 500 and Dow slip on a crude oil slump.

Biotech Insider Just Loaded Up $234 Million Worth the Stock

Biotech Insider Just Loaded Up $234 Million Worth the Stock

Massive biotech bet!

Energy Sector Pressures the Dow and S&P 500 as Crude Selloff Steepens

Energy Sector Pressures the Dow and S&P 500 as Crude Selloff Steepens

Stocks are mixed as energy lags, health care leads.

Chipotle's Rally Could Resume

Chipotle's Rally Could Resume

I am starting to watch a couple of key price zones on the way down.

Jim Cramer: Another Rotation Out of Apple and Nvidia Is in the Cards

Jim Cramer: Another Rotation Out of Apple and Nvidia Is in the Cards

We forget that a big hedge fund or mutual fund switching out of tech winners into everything else can roil the market.

Why Alexion's Gain In the C-Suite Doesn't Bode Well For Biogen Takeout Prospects

Why Alexion's Gain In the C-Suite Doesn't Bode Well For Biogen Takeout Prospects

Paul Clancy's move to another biotech firm could mean that there's nothing imminent in terms of Biogen being bought out, says Mizuho analyst Salim Syed.

Cramer: The Rotation Out of Apple and Nvidia Can Happen Again Today

Cramer: The Rotation Out of Apple and Nvidia Can Happen Again Today

We forget that a big hedge fund or mutual fund switching out of tech winners into everything else can roil the market.

Alexion Pops, Biogen Falls on Executive Shuffle; Epizyme Recovers As Investors Digest Phase 2 Data

Alexion Pops, Biogen Falls on Executive Shuffle; Epizyme Recovers As Investors Digest Phase 2 Data

Epizyme, Alexion Pharmaceuticals and XBiotech were among the biotech stock movers premarket trading on June 14.

Biogen CFO Bolts to Alexion

Biogen CFO Bolts to Alexion

Chief accounting officer Greg Covino will serve as Biogen's interim principal financial officer while the firm searches for a new finance chief.

Alexion Names Paul Clancy Chief Financial Officer

Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) today announced that Paul J.

Alexion Announces Additions To Executive Leadership Team

Alexion Pharmaceuticals Inc. (NASDAQ:ALXN) today announced key additions to its executive leadership team effective June 5, 2017.

Small-Cap Action Is Improving

Small-Cap Action Is Improving

But I don't have a lot of confidence in this market beyond the intraday action.

Biotech Movers: Akari, Array, Amicus

Biotech Movers: Akari, Array, Amicus

Akari Therapeutics, Array BioPharma and Amicus Therapeutics were among the biotech movers in premarket trading on Wednesday.

Looking for the End of a Trend

Looking for the End of a Trend

Alexion Pharmaceuticals presents a tradeable countertrend opportunity.

Alexion Pharma: Negative Market Sentiment Creates Buying Opportunity

Alexion Pharma: Negative Market Sentiment Creates Buying Opportunity

I think the market is obsessing over the Alexion negatives and not looking at the real potential for positive catalysts ahead.

Alexion To Present At Upcoming Investor Conferences

Alexion Pharmaceuticals, Inc. (Nasdaq: ALXN) today announced that management will present at two upcoming investor conferences: Goldman Sachs 38th Annual Global Healthcare Conference in Rancho Palos Verdes on...

The Good, the Bad and the Ugly; Explaining the Inexplicable: Doug Kass' Views

The Good, the Bad and the Ugly; Explaining the Inexplicable: Doug Kass' Views

Doug Kass shares his thoughts on trying to explain that which cannot be explained, and also discusses what was good (and bad and ugly) this week.

Analysts' Actions -- Kellogg, Kraft Heinz, Altria, PayPal and More

Analysts' Actions -- Kellogg, Kraft Heinz, Altria, PayPal and More

Here are Thursday's top research calls, including new coverage for Kellogg, Kraft Heinz and Altria, and a downgrade for PayPal.

Trader's Daily Notebook: As Long Weekend Nears, Volume Will Stay Low

Trader's Daily Notebook: As Long Weekend Nears, Volume Will Stay Low

If you want to stay active, you'll have to do more homework.

Alexion Shares Drop Amid Executive Changes

Alexion Shares Drop Amid Executive Changes

The biopharmaceutical firm on Tuesday announced changes, including the planned departure of its chief financial officer.

BMO: Too Early to Tell If Alexion's Management Shakeup Bodes Well for Stock

BMO: Too Early to Tell If Alexion's Management Shakeup Bodes Well for Stock

The biopharmaceutical firm's CFO announced today that he will be leaving in August.

Biotech Movers: Cerus, Alexion, NantKwest

Biotech Movers: Cerus, Alexion, NantKwest

Cerus, Alexion Pharmaceuticals and NantKwest were among the biotech movers in premarket trading on Tuesday.

TheStreet Quant Rating: C (Hold)